Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology

Int J Gynecol Cancer. 2004 Jan-Feb;14(1):12-22. doi: 10.1111/j.1048-891x.2004.14224.x.


The advent of positron emission tomography (PET) and PET/computed tomography (CT) now enables us to detect metabolically active gynecologic cancers with greater accuracy than was possible with anatomic imagings. Fluorine-18 fluorodeoxyglucose PET has been useful in differentiation of malignant from benign lymph nodes, and residual or recurrent cancers from post-treatment changes. PET/CT produces additional information for the diagnosis and tissue biopsy as well as radiotherapy planning. This paper reviews the principle and clinical utility of PET and PET/CT in the diagnosis, staging, recurrence, therapeutic response as well as prognosis of gynecologic cancers.

Publication types

  • Review

MeSH terms

  • Female
  • Fluorodeoxyglucose F18
  • Genital Diseases, Female / diagnosis*
  • Genital Diseases, Female / diagnostic imaging
  • Humans
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasm Recurrence, Local / diagnostic imaging
  • Neoplasm Staging
  • Radiopharmaceuticals
  • Tomography, Emission-Computed*
  • Tomography, X-Ray Computed*


  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18